Nightingale Health’s Board of Directors extended the subscription period of employee option rights

Company release

23 May 2024 at 10:45 a.m. (EEST)

 

Nightingale Health Plc’s (“Nightingale Health”) Board of Directors resolved to extend the subscription period of option rights in the stock option program for key employees. The subscription period of option rights in the stock option program for key employees ended on 31 December 2023, and the Board of Directors resolved to continue the subscription period until 31 December 2028.

 

The size of the stock option program remains the same and no new stock options were issued. All terms and conditions for the employee stock option program also remain unchanged. 

 

The stock option program for key employees was launched in March 2022 based on the authorisation granted by the Extraordinary General Meeting held on 18 February 2021. The total number of option rights that can be issued based on the stock option program for key employees is 2.5 million stock options and each option right entitles the option holder to subscribe for one Series B share. The right to subscribe shares is earned solely based on reaching market capitalisation steps of at least EUR 500 million and EUR 1,000 million calculated with the volume weighted average price.

 

By the end of 2023, approximately 45% of the 2.5 million stock options were unused and remain in the stock option pool. The decision to continue the subscription period was done to enable the continuous use of stock options in recruitments and incentivizing key employees to contribute to the growth and value increase of the company.

 

 

For further information, please contact:

Teemu Suna, CEO
[email protected]

 

Certified advisor:

Oaklins Merasco Ltd, tel. +358 9 6129 670

 

About Nightingale Health

 

Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

 

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com